Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-012 in non-metastatic hepatocellular carcinoma
NL-OMON52824Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib, pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Merck & Co.. Started May 2021; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON52824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52824.